| Year | Milestone | |------|-----------| | | Hit identification via high‑throughput screening of ~2 M compounds. | | 2023 | Lead optimization; PRED‑462 selected for superior potency and ADME profile. | | 2024 | IND‑enabling toxicology completed; filing of a provisional patent. | | 2025 | First‑in‑human (FIH) Phase I trial initiated in healthy volunteers (single‑ascending dose). | | 2026 (Projected) | Expansion into Phase Ib/IIa oncology trial in estrogen‑receptor‑positive (ER⁺) breast cancer patients. |
The journey from conceptualization to realization of a project or compound like PRED-462 involves rigorous research and development (R&D). This process typically includes:
The PRED-462 is the latest innovation in high-performance computing, designed to meet the needs of data centers, research institutions, and industries requiring intensive computational power.
| Year | Milestone | |------|-----------| | | Hit identification via high‑throughput screening of ~2 M compounds. | | 2023 | Lead optimization; PRED‑462 selected for superior potency and ADME profile. | | 2024 | IND‑enabling toxicology completed; filing of a provisional patent. | | 2025 | First‑in‑human (FIH) Phase I trial initiated in healthy volunteers (single‑ascending dose). | | 2026 (Projected) | Expansion into Phase Ib/IIa oncology trial in estrogen‑receptor‑positive (ER⁺) breast cancer patients. |
The journey from conceptualization to realization of a project or compound like PRED-462 involves rigorous research and development (R&D). This process typically includes: PRED-462
The PRED-462 is the latest innovation in high-performance computing, designed to meet the needs of data centers, research institutions, and industries requiring intensive computational power. | Year | Milestone | |------|-----------| | |